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Abstract
Background: Transient receptor potential ankyrin 1 (TRPA1) channel plays an important role in pain and inflammation.
However, little is known about the significance of the TRPA1 channel in the pathophysiology of Alzheimer’s disease (AD).
Methods: Wild-type (WT), TRPA1−/−, amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic (APP/PS1 Tg) mice,
the mouse model of AD, and APP/PS1 Tg/TRPA1−/− mice were used to examine the role of TRPA1 in pathogenesis of AD.
Western blot was used for protein expression; immunohistochemistry was used for histological examination. The mouse
behaviors were evaluated by locomotion, nesting building, Y-maze and Morris water maze tests; levels of interleukin
(IL)-1β, IL-4, IL-6 and IL-10 and the activities of protein phosphatase 2B (PP2B), NF-κB and nuclear factor of activated T cells
(NFAT) were measured by conventional assay kits; Fluo-8 NW calcium (Ca2+) assay kit was used for the measurement of
intracellular Ca2+ level in primary astrocytes and HEK293 cells.
Results: The protein expression of TRPA1 channels was higher in brains, mainly astrocytes of the hippocampus,
from APP/PS1 Tg mice than WT mice. Ablation of TRPA1-channel function in APP/PS1 Tg mice alleviated behavioral
dysfunction, Aβ plaque deposition and pro-inflammatory cytokine production but increased astrogliosis in brain lesions.
TRPA1 channels were activated and Ca2+ influx was elicited in both astrocytes and TRPA1-transfected HEK293 cells treated
with fibrilized Aβ1–42; these were abrogated by pharmacological inhibition of TRPA1 channel activity, disruption of TRPA1
channel function or removal of extracellular Ca2+. Inhibition of TRPA1 channel activity exacerbated Aβ1–42–induced
astrogliosis but inhibited Aβ1–42–increased PP2B activation, the production of pro-inflammatory cytokines and activities of
transcriptional factors NF-κB and NFAT in astrocytes and in APP/PS1 Tg mice. Pharmacological inhibition of PP2B activity
diminished the fibrilized Aβ1–42–induced production of pro-inflammatory cytokines, activation of NF-κB and NFAT and
astrogliosis in astrocytes.
Conclusions: TRPA1 − Ca2+ − PP2B signaling may play a crucial role in regulating astrocyte-derived inflammation and
pathogenesis of AD.
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Background
Alzheimer's disease (AD), a progressive neurodegenerative
disease, is the most common cause of dementia [1]. The
typical symptoms of AD include learning and memory loss
and cognitive impairment [1, 2]. Amyloid-β (Aβ) plaque
deposition is one of the major pathological hallmarks in
AD [2–4]. Aβ is generated from amyloid precursor protein
(APP) by β-site APP cleavage enzyme 1 (BACE1) and
presenilin 1 (PS1) [3, 5]. The toxic Aβ activates astrocytes
and microglia to trigger chronic inflammation, thereby
releasing cytokines, pro-inflammatory mediators and react-
ive oxygen species (ROS) and leading to progression of AD
[6–10]. Several lines of evidence suggest that Aβ-mobilized
calcium (Ca2+) flow is closely associated with the inflam-
matory response in astrocytes [11–13]. On Aβ stimulation,
elevated intracellular Ca2+ level promotes cytokine secre-
tion by activating protein phosphatase 2B (PP2B, also
called calcineurin) and its downstream NF-κB and nu-
clear factor of activated T cells (NFAT) [14–16]. How-
ever, which type of cation channel is responsible for the
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Aβ-activated Ca2+ signaling and inflammation remains
for further investigation.
Transient receptor potential ankyrin 1 (TRPA1) channel
is a type of nonselective transmembrane cation channel
with multiple ankyrin repeats on its N-terminal [17–20].
TRPA1 channel is expressed in primary sensory neurons
and non-neuronal cells and may be a sensor for detecting
ROS, cold temperature and cannabinoids [21–24]. Upon
detection of these signals, the TRPA1 channel is activated,
which results in increased intracellular Ca2+ levels and
activated downstream signaling cascades [17–20]. In the
brain, the TRPA1 channel plays an important role in regu-
lating brain development and the physiological function of
astrocytes [24, 25]. In addition, it may be a key gatekeeper
in regulating the inflammatory response with stimuli
including bacterial endotoxin, environmental irritants or
inflammatory mediators [26–28]. Recently, AD research
has focused on the emerging role of Ca2+-related signaling
pathways in the pathogenesis of AD [29, 30]. However,
the role and underlying molecular mechanism(s) of the
TRPA1–Ca2+ signaling cascade in AD pathogenesis are
still elusive.
In this study, we aimed to investigate the role of TRPA1
channels in AD pathogenesis and the possible molecular
mechanisms in a mouse model. We determined the expres-
sion of TRPA1 channels in vivo by using wild-type (WT)
and APP/PS1 transgenic (Tg) mice, then investigated
whether the TRPA1 channel plays a role in the develop-
ment of AD by using APP/PS1 Tg and APP/PS1 Tg/TRPA1
−/− mice. Finally, we assessed the importance of TRPA1 and
the potential mechanism underlying the regulation of Aβ-
mediated inflammation in mice and astrocytes.
Methods
Reagents
Rabbit antibody for TRPA1 (NB110-40763) was from
Novus (Littleton, CO, USA). Goat antibody for Akt (sc-
1619), rabbit antibodies for PP2B (sc-9070), mouse anti-
bodies for glial fibrillary acidic protein (GFAP, sc-
166481), goat anti-rabbit FITC-conjugated (sc-2012),
goat anti- mouse Texas red-conjugated (sc-2781) and
FITC-conjugated (sc-2010) antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Mouse
antibodies for GFAP (MAB360), NeuN (MAB3770),
ionized calcium-binding adapter molecule 1 (IBA-1,
MABN92), von Willebrand factor (vWF, MAB7356),
and the cellular PP2B activity kit were from Millipore
(Darmstadt, Germany). Rabbit LDLR-related protein 1
(LRP-1, L2170), mouse antibody for α-tubulin (T-9026), bo-
vine serum albumin (BSA), phosphatase inhibitor cocktails
1 and 2, HC030031, allyl isothiocyanate (AITC), ethylene
glycol tetraaceticacid (EGTA), ethylenediaminetetraacetic
acid (EDTA), cyclosporine (CsA) and fenvalerate (Fen) were
from Sigma-Aldrich (St. Louis, MO, USA). Mouse antibody
for Aβ (SIG-39320-200) was from Covance (Dedham, MA,
USA). Rabbit antibody for β-APP C-terminal fragment
(βCTF, 802801) was from BioLegend (San Diego, CA,
USA). Mouse antibody for ATP-binding cassette trans-
porter A1 (ABCA1, ab18180), IL-4 (ab9622) and IL-10
(ab9969) were from Abcam (Cambridge, MA, UK). Rabbit
antibody for apolipoprotein E (apoE, 1930-5) was from Epi-
tomics (Burlingame, CA, USA). Mouse anti-phosphor-Akt
(587 F11) was from Cell Signaling (Danvers, MA, USA).
Retrieval buffer was from Biocare Medical (Concord, CA,
USA). The mounting medium with DAPI was from Vector
Laboratories (Burlingame, CA, USA). TurboFect was from
Fermentas (Glen Burnie, MD, USA). The ELISA kit for NF-
κB activity was from Cayman Chemical (Ann Arbor, MI,
USA) and for NFAT activity was from Active Motif (Carls-
bad, CA, USA). ELISA kits for IL-1β, IL-4, IL-6 and IL-10
and mouse antibodies for IL-1β (AF-401-NA) and IL-10
(AF-406-NA) were from R&D systems (Minneapolis, MN,
USA). Quest™ Fluo-8 NW calcium assay kit was from AAT
Bioquest (Sunnyvale, CA, USA).
Mice
The investigation conformed to the Guide for the Care and
Use of Laboratory Animals (Institute of Laboratory Animal
Resources, eighth edition, 2011), and all animal experi-
ments were performed in accordance with the approved
guidelines by the Animal Care and Utilization Committee
of the National Yang-Ming University (#1031269). B6.Cg-
Tg(APPswe, PSEN1dE9)85Dbo/J (APP/PS1 Tg) mice and
TRPA1−/− mice were purchased from Jackson Laboratory
(Bar Harbor, ME, USA) and were backcrossed to C57BL
mice for at least 10 generations to ensure genetic homogen-
eity. For APP/PS1 Tg/TRPA1−/− mice, TRPA1−/− mice were
crossed with the APP/PS1 Tg background, and the geno-
types were confirmed by PCR of genomic DNA. Mice were
housed in barrier facilities, maintained on a 12-h/12-h dark
cycle. Temperature (22 °C) and humidity (40-60 %) of the
vivarium were tightly controlled. Mice were group-housed
3–4 per cage and fed a regular chow diet, which contained
4.5 % fat by weight (0.02 % cholesterol) (Newco Distribu-
tors, Redwood, CA, USA). At the end of the experiment,
mice were euthanized with CO2, then brains were har-
vested for histological analysis and stored at −80 °C.
The isolated brains were homogenized and lysates were
subjected to western blot analysis.
Western blot analysis
Cells and brain tissues were lysed in immunoprecipita-
tion lysis buffer (50 mmol/L Tris pH 7.5, 5 mmol/L
EDTA, 300 mmol/L NaCl, 1 % Triton X-100, 1 mmol/L
phenylmethylsulfonyl fluoride, 10 μg/mL leupeptin and
10 μg/mL aprotinin). Aliquots of brain lysates or cell
lysates were separated on SDS-PAGE, transferred to
membranes and immunoblotted with primary antibodies
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(1:1000), then horseradish peroxidase-conjugated second-
ary antibody (1:1000). Bands were revealed by use of an
enzyme-linked chemiluminescence detection kit (Perki-
mElmer, Waltham, MA) and density was quantified by use
of Imagequant 5.2 (Healthcare Bio-Sciences, Philadelphia,
PA).
Immunohistochemistry staining
The brain sections were fixed in 4 % paraformaldehyde
and 15-μm cross sections were prepared. Sections were
incubated with retrieval buffer for 10 min, blocked with
2 % BSA for 60 min and incubated with primary anti-
body (1:100) overnight at 4 °C, then FITC- or Texas red-
conjugated secondary antibody (1:400) for 1 h at 37 °C.
Antigenic sites were visualized under a Nikon TE2000-
U microscope (Tokyo) with QCapture Pro 6.0 software
(QImaging, BC, Canada).
Fibrilization of Aβ1–42
Aβ1–42 was purchased from American Peptide Co. (Sunny-
vale, CA, USA), solubilized in sterile water (1 mg/mL) and
incubated 1 to 7 days at 37 °C for fibrillation as described
[31–33]. The level of Aβ fibrilization on a 16.5 % tricine gel
was examined by western blot analysis (Additional file 1:
Figure S1).
Cell culture
The primary culture of astrocytes and neurons was pre-
pared as described [24, 34]. Briefly, the cortex and hippo-
campus were isolated from pups on postnatal 1 day and
loosely homogenized by use of a sterile razor blade in
DMEM/F12 (HyClone, Logan, UT). Tissues were digested
with 0.01 % trypsin and incubated at 37 °C for 25 min; the
cell suspension was titrated by use of a 70-μm nylon mesh.
Isolated cells were seeded onto 75-mm flasks and incubated
for 7 days in DMEM/F12 supplemented with 10 % FBS,
100 U/mL penicillin and 100 μg/mL streptomycin at 37 °C.
Cells were re-suspended, followed by orbital shaking at
180 rpm for 24 h to remove microglia and oligodendro-
cytes. The purified astrocytes that tightly adhered to the
bottom of the flasks were then detached with trypsin and
seeded onto culture dishes and incubated for an additional
7 days to return to a resting state. The primary neuron
culture was prepared as follows: the cortex was isolated
from pups on postnatal 1 day and loosely homogenized by
use of a sterile razor blade in DMEM (HyClone, Logan,
UT). Isolated cells were seeded onto 3.5-cm dishes and
incubated in Neurobasal media supplemented with 2 % B-
27 supplement, 0.25 % GlutaMAX, 10 % FBS, 100 U/mL
penicillin and 100 μg/mL streptomycin (Thermo Fisher
Scientific, Waltham, MA, USA) at 37 °C. Cells were treated
with cytosine-1-β-D-arabinofuranoside (10 μM) from day 2
and half the medium was changed every 3 days for 14 days’
culture. Human embryonic kidney 293 (HEK293) cells and
mouse brain microvascular endothelial cells (BMECs),
bEnd.3 cells, were cultured in DMEM supplemented
with 10 % FBS, 100 U/mL penicillin and 100 μg/mL
streptomycin. The growth media was replaced every other
day.
Plasmid construction and transient transfection
The coding region for the human TRPA1 DNA fragment
was cloned into a pCMV5 N-Flag vector with MluI and
HindIII restriction sites. The sequence of isolated DNA
fragments was confirmed by sequence analysis. TurboFect
was used for transient transfection experiments according
to the manufacturer’s instructions. Briefly, 1 μg of vector
or TRPA1 plasmid was transfected into HEK293 cells.
Transfected cells were used in further experiments.
Detection of Ca2+ influx
Primary astrocytes or HEK293 cells were pretreated with
Fluo-8NW dye for 1 h, then medium was replaced with
fresh medium containing test compounds. The intensity
of fluorescence was evaluated by fluorometry (Molecular
Devices, Sunnyvale, CA, USA) with 490-nm excitation
and 525-nm emission. Images were captured under a
TE2000-U fluorescence microscope and quantified with
use of QCapture Pro 6.0.
Measurement of PP2B activity
The activity of PP2B in primary astrocytes or fresh brain
lysates was measured by use of a cellular PP2B activity
kit.
Measurement of inflammatory cytokines
The concentrations of inflammatory cytokines including
IL-1β, IL-4, IL-6 and IL-10 in culture medium or brain
lysates were measured by use of ELISA kits.
Measurement of DNA-binding activity on NF-κB and NFAT
The DNA-binding activity of NF-κB and NFAT in primary
astrocytes and brain was measured by use of ELISA kits.
Immunocytochemical staining
Primary astrocytes were fixed with 4 % paraformaldehyde
for 30 min, blocked with 2 % BSA for 30 min and incubated
with primary antibodies (1:100), then FITC- or Texas red-
conjugated secondary antibodies (1:400). Cellular images
were viewed under a TE2000-U fluorescence microscope
and quantified with use of QCapture Pro 6.0.
Open field activity
The locomotor activity of mice was assessed in a cage
(length × width × height: 28.5 × 28.5 × 30 cm). Mice were
placed in the central of the cage and allowed to explore
the open field for 5 min. The behavior was recorded by
video, and the movement distance, percentage of resting
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time in the zone and trajectory were calculated for each
mouse by use of Smart v3.0 software with the Panlab
Harvard apparatus (Cornellà, Barcelona, Spain). The floor
and internal walls were cleaned with ethanol between each
trial.
Nest-building test
The nest-building test was performed as described [35].
Each mouse was housed in single cages containing two
pieces of cotton (5 × 5 cm). The presence and quality of
nests built were recorded by the nesting score, measured
on a 5-point scale: 1 = cotton not noticeably touched, 2
= cotton partially torn up, 3 =mostly shredded cotton
but often no identifiable nest location, 4 = a markedly
nesting site but flat nest, and 5 = a (near) perfect nest.
Nesting score was recorded manually at 72-h intervals.
Y-maze test
The Y-maze test was performed as described [36]. The
Y-maze apparatus consists of three arms of channels
made of stainless steel joined in the middle to form a
“Y” shape. The mice were placed into one of the arms
(start arm) and allowed to explore the maze with only
one of the arms closed for 10 min (training trial). After
3 h, mice were placed back in the start arm of the Y
maze. Then, mice were allowed to explore all three arms
freely for 5 min (test trial). The number of entries into
each arm, the distance of movement and the first choice
of entry were assessed in video recordings.
Morris water maze (MWM)
MWM was performed as described [36]. A large circular
tank (0.8 m diameter, 0.4 m depth) was filled with water
(25 ± 1 °C, 20 cm depth), and the escape platform (8 ×
4 cm) was submerged 1 cm below the surface. The train-
ing section was monitored by a video system. The escape
latency and trajectory of swimming were recorded for
each mouse. The hidden platform was located at the
center of one of the four quadrants in the tank. The loca-
tion of the platform was fixed throughout the testing.
Mice had to navigate using extra-maze cues that were
placed on the walls of the maze. From days 1 to 4, mice
went through three trials with an inter-trial interval of
5 min. The mouse was placed into the tank facing the side
wall randomly at one of four start locations and allowed
to swim until it found the platform or for a maximum of
120 sec. Mice that failed to find the platform within
120 sec were guided toward the platform. The animal then
remained on the platform for 20 sec before being removed
from the pool. The day after the hidden platform training,
a probe trial was conducted to determine whether the
mouse used a spatial strategy to find the platform. On day
5, the platform was removed from the pool and the mouse
was allowed to swim freely for 120 sec. The proportion of
time spent in each quadrant of the pool and the number
of times the mouse crossed the former position of the hid-
den platform were recorded.
Statistical analysis
Results are presented as mean ± SEM. Data from cell
studies were evaluated by non-parametric tests. Mann-
Whitney U test was used to compare 2 independent
groups. Kruskal-Wallis followed by Bonferroni post-hoc
analyses was used to account for multiple testing. Data
from animal studies were evaluated by parametric tests.
Two-way ANOVA followed by LSD test was used for
multiple comparisons. The reagent effect and genotypic
effect were two independent factors for this analysis.
SPSS v20.0 (SPSS Inc, Chicago, IL) was used for analysis.
Differences were considered statistically significant at
P < 0.05.
Results
The expression of TRPA1 channels is upregulated in
astrocytes of AD lesions
To explore the possible participation of TRPA1 channels
in the pathogenesis of AD, we investigated the expres-
sion and distribution of TRPA1 channels in brains from
WT and APP/PS1 Tg mice. The protein level of TRPA1
channels was higher in APP/PS1 Tg than WT mice at
8 months old (Fig. 1a, n = 6, P < 0.05). However, the
protein level did not differ between APP/PS1 Tg and
WT mice at 3 months old (Additional file 1: Figure S2,
n = 6, P > 0.05). In the cortex, TRPA1 channels were
expressed in endothelial cells of both WT and APP/PS1
Tg mice (Fig. 1b, c). However, the immunoreactivity of
TRPA1 channels in neurons was observed only in APP/
PS1 Tg mice (Fig. 1b, c). In the hippocampus, TRPA1
channels were expressed in astrocytes of both WT and
APP/PS1 Tg mice; however, TRPA1 level in hippocam-
pus astrocytes was greater in APP/PS1 Tg than WT mice
(Fig. 1b, c). In WT mice, the protein level of TRPA1 was
much lower in neurons than astrocytes and BMECs
(Additional file 1: Figure S3). TRPA1 may play an im-
portant role in astrocyte biology in AD pathogenesis.
Genetic loss of function of TRPA1 channels on an APP/
PS1 Tg background improves nest building and spatial
learning and memory
To assess the effect of TRPA1 channels in the pathophysi-
ology of AD, we generated APP/PS1 Tg/TRPA1−/− mice
(Fig. 2a). APP/PS1 Tg/TRPA1−/− mice showed better per-
formance in nest building than APP/PS1 Tg mice at
8 months old (Fig. 2b, c, n = 8, P < 0.05). In the Y-maze
test, 8-month-old APP/PS1 Tg/TRPA1−/− mice showed
increased preference for first entry to a novel arm; the ra-
tio of entry number and moving distance in the novel arm
was greater in these mice than in 8-month-old APP/PS1
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Tg mice (Fig. 2d-g, n = 8, P < 0.05). Next, the MWM test
was performed to evaluate the ability of spatial learning
and memory of mice. With the hidden platform test, both
APP/PS1 Tg and APP/PS1 Tg/TRPA1−/− mice learned the
location of the hidden platform on day 3 and 4; however, 8-
month-old APP/PS1 Tg/TRPA1−/− mice showed shorter
escape latencies, which indicates better learning patterns,
than APP/PS1 Tg mice with a 4-day training (Fig. 2h, n = 8,
Fig. 1 Expression and localization of TRPA1 channels in wild-type (WT) and APP/PS1 Tg mice. (a) Brains were harvested from WT and APP/PS1 Tg mice
at 8 months old. Western blot analysis of protein levels of TRPA1 and α-tubulin. Data are mean ± SEM from 6 mice in each group. *, P< 0.05 vs. WT mice.
(b, c) Immunohistochemistry of specimens of cortex and hippocampus from 8-month-old WT and APP/PS1 Tg mice with the antibodies anti-TRPA1,
anti-vWF (endothelial cell marker), anti-NeuN (neuron marker), anti-GFAP (astrocyte marker) and anti-IBA-1 (microglia marker), then FITC- or Texas
red-conjugated secondary antibody. Bar = 50 μm. vWF-positive cells denoted endothelial cells, NeuN-positive cells denoted neurons, and GFAP-positive
cells denoted astrocytes, as indicated by arrowheads, stars or arrows, respectively
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P < 0.05). Moreover, APP/PS1 Tg/TRPA1−/− mice showed
increased number of times crossing the hidden platform
and retention times in the target quadrant (quadrant 4) at
day 5 after training (Fig. 2i, j, n = 8, P < 0.05). The genotypes
did not differ in swimming to the visual platform test
(Fig. 2k). However, WT, TRPA1−/−, APP/PS1 Tg and
APP/PS1 Tg/TRPA1−/− mice showed no difference in
the above behaviors and locomotion (Additional file 1:
Figure S4, n = 8, P > 0.05). These findings suggest that the
TRPA1 channel might be a key regulator in AD-related
cognitive performance behavior and spatial learning and
memory.
Genetic ablation of function of TRPA1 channels on an
APP/PS1 Tg background decreases Aβ deposition in brain
lesions and mitigates inflammation but aggravates
astrogliosis
To investigate the potential molecular mechanism of
TRPA1 channels underlying AD pathogenesis and Aβ-
triggered inflammation, we examined Aβ plaque deposition
in AD lesions of APP/PS1 Tg and APP/PS1 Tg/TRPA1
−/− mice. Aβ plaque deposition was markedly decreased
in cortex and hippocampus of APP/PS1 Tg/TRPA1−/−
mice (Fig. 3a). Western blot results of Aβ in both oligo-
mers and monomers and βCTF within brain lysates
from APP/PS1 Tg and APP/PS1 Tg/TRPA1−/− mice
supported the decreased Aβ plaque deposition in APP/
PS1 Tg/TRPA1−/− mice (Fig. 3b, n = 8, P < 0.05). The
expression of ABCA1, LRP-1 (n = 8, P < 0.05) but not
apoE (n = 8, P > 0.05) was decreased in APP/PS1 Tg/
TRPA1−/− mice (Fig. 3c). However, astrogliosis was
more severe in APP/PS1 Tg/TRPA1−/− than APP/PS1
Tg mice (Fig. 4a, b, n = 8, P < 0.05). Functional loss of
TRPA1 channels markedly reduced the levels of the
inflammatory cytokines IL-1β, IL-6 and IL-4 (n = 8, P <
0.05) but not anti-inflammatory cytokine IL-10 (n = 8,
P > 0.05) in AD brains (Fig. 4c-f ). We next evaluated
the activity of NF-κB and NFAT, major transcription
factors regulating the expression of IL-1β, IL-6, IL-4
and IL-10 [37–40]. DNA-binding activities of both NF-
Fig. 2 Loss of function of TRPA1 channels improves nest building and spatial learning and memory in APP/PS1 Tg mice. (a) PCR genotyping of
representative WT, TRPA1−/−, APP/PS1 Tg and APP/PS1 Tg/TRPA1−/− mice. PS1 = 608 bp, APP = 377 bp, TRPA1+/+ = 317 bp and TRPA1−/− = 184 bp.
(b, c) Representative examples and the score for nest building for 8-month-old WT, TRPA1−/−, APP/PS1 Tg and APP/PS1 Tg/TRPA1−/− mice. (d-g)
Schematic diagram of Y-maze experimental design and ratio of first entry, number of entries and distance moved in the novel arm. (h) Morris water
maze (MWM) test of learning patterns verified on days 1 to 4. (i, j) At day 5 after training, the number of times crossing the hind platform and retention
times in the all quadrants. (k) The latency of arrival to the visual platform. Data are mean ± SEM from 8 mice in each group. *, P < 0.05 vs. WT mice or day
1 (h panel), #, P< 0.05 vs. APP/PS1 Tg mice, $ P< 0.05 vs. WT mice (h panel)
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κB and NFAT were lower with functional deletion of
the TRPA1 channel in APP/PS1 Tg/TRPA1−/− mice
than in APP/PS1 Tg mice (Fig. 4g, h, n = 8, P < 0.05).
Immunohistochemistry revealed that IL-1β, IL-6, IL-4
and IL-10 were mainly expressed in astrocytes of APP/
PS1 Tg and APP/PS1 Tg/TRPA1−/− mice (Fig. 4i). How-
ever, functional ablation of TRPA1 channels on the
C57BL background did not induce Aβ deposition and
inflammation in brains (Fig. 3, 4, n = 8, P > 0.05) but
increased astrogliosis (Fig. 4a, b, n = 8, P < 0.05). The
TRPA1 channel may be a key player in regulating Aβ
metabolism and inflammatory responses during AD
development.
Aβ − elicited increase in intracellular Ca2+ in astrocytes is
TRPA1-dependent
To examine the potential role of TRPA1 channels in the
detrimental effect of Aβ on AD, we first detected the
expression of the TRPA1 channel in astrocytes (Fig. 5a).
Treatment with fibrilized Aβ did not changes the expres-
sion of TRPA1 channels in astrocytes over time (Fig. 5b,
n = 5, P > 0.05). We then investigated whether Aβ could
induce functional activation of TRPA1 in astrocytes by
treating WT astrocytes with 2 μM Aβ for the indicated
times. Compared with vehicle treatment, Aβ treatment
time-dependently promoted Ca2+ influx within 60 min.
The elevated intracellular Ca2+ level occurred as early as
Fig. 3 Ablation of TRPA1 channel function decreases Aβ deposition in brain lesions of APP/PS1 Tg mice. (a) Immunostaining of specimens of
hippocampus and cortex from 8-month-old WT, TRPA1−/−, APP/PS1 Tg and APP/PS1 Tg/TRPA1−/− mice with anti-Aβ antibody, then FITC-conjugated
secondary antibody. (b, c) Western blot analysis of protein levels of oligomer (oligo) or monomer (mono) Aβ, βCTF, ABCA1, LRP-1, apoE and α-tubulin
in brain specimens. Bar = 100 μm. Data are mean ± SEM from 8 mice in each group. *, P < 0.05 vs. WT mice. #, P < 0.05 vs. APP/PS1 Tg mice
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2 min after treatment (Fig. 5c, n = 5, P < 0.05). Add-
itionally, functional deletion of TRPA1, treatment with
TRPA1 pharmacological inhibitor HC030031, and pre-
treatment with EGTA or EDTA all abrogated the fibrilized
Aβ-increased intracellular Ca2+ level in astrocytes (Fig. 5d-
g, n = 5, P < 0.05). To further investigate the involvement
of TRPA1 in Aβ-induced Ca2+ influx, we re-expressed
full-length human TRPA1 channels in HEK293 cells,
which lack TRPA1 channels. TRPA1 channels were suc-
cessfully expressed in HEK293 cells (Fig. 6a). Treatment
with both Aβ and AITC, a TRPA1 selective agonist, sig-
nificantly increased intracellular Ca2+ level in TRPA1-
positive HEK293 cells as compared with empty vector–
transfected cells, with the increase in intracellular Ca2+
Fig. 4 Genetic disruption of TRPA1 channel function increases astrogliosis but decreases inflammation in hippocampus of APP/PS1 Tg mice.
(a) Immunostaining of hippocampus specimens from 8-month-old WT, TRPA1−/−, APP/PS1 Tg and APP/PS1 Tg/TRPA1−/− mice with anti-GFAP
antibody, then Texas red-conjugated secondary antibody. (b) Western blot analysis of protein levels of GFAP and α-tubulin. ELISA of (c-f) IL-1β,
IL-6, IL-4 and IL-10 secretion and (g, h) NF-κB and NFAT DNA binding activity in brain specimens from 8-month-old WT, TRPA1−/−, APP/PS1 Tg
and APP/PS1 Tg/TRPA1−/− mice. (i) Immunostaining of hippocampus specimens from 8-month-old APP/PS1 Tg and APP/PS1 Tg/TRPA1−/− mice
with the antibodies anti-GFAP, anti-IL-1β, IL-6, IL-4 or IL-10, then FITC- or Texas red-conjugated secondary antibody. Bar = 50 μm. GFAP-positive
cells (red color) denote astrocytes; IL-1β-, IL-6-, IL-4- and IL-10-positive astrocytes (green color) are indicated by arrowheads, arrows, stars or dots,
respectively. Data are mean ± SEM from 8 mice in each group. *, P < 0.05 vs. WT mice. #, P < 0.05 vs. APP/PS1 Tg mice
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level observed with 1- to 60-min Aβ treatment (Fig. 6b, c,
n = 5, P < 0.05). Blockage of TRPA1 activation by the
TRPA1 selective antagonist HC030031 or removal of
extracellular Ca2+ by EGTA or EDTA abrogated Aβ-
induced Ca2+ influx in TRPA1-reexpressed HEK293
cells (Fig. 6d, n = 5, P < 0.05). Therefore, TRPA1 is es-
sential for Aβ-induced Ca2+ mobilization.
TRPA1 − Ca2+ signaling plays a crucial role in Aβ-mediated
PP2B activation, inflammatory responses and astrogliosis in
astrocytes
Emerging evidence indicates that Aβ-elevated intracel-
lular Ca2+ level may trigger pro-inflammatory cytokine
production by activating PP2B and its downstream
transcription factors such as NF-κB and NFAT [14–16].
Therefore, we examined whether TRPA1-Ca2+ signaling
is involved in Aβ-induced activation of PP2B, the
DNA-binding activities of its downstream targets NF-
κB and NFAT, and subsequent inflammatory responses
both in vivo and in vitro. We investigated the significance
of TRPA1 channels in astrocytes with Aβ treatment in
terms of inflammatory responses and astrogliosis. Low
fibrilization Aβ triggered the production of IL-4 and IL-10
in astrocytes, whereas high fibrilization stimulated the
production of IL-1β and IL-6 (Additional file 1: Figure S1,
n = 5, P < 0.05). With high fibrillation of Aβ, functional
Fig. 5 Aβ elicits TRPA1-dependent Ca2+ influx in astrocytes. (a) Immunostaining of primary astrocytes from WT mice with anti-IgG and anti-TRPA1
antibody, then FITC-conjugated secondary antibody. (b) Western blot analysis of TRPA1 and α-tubulin protein levels in astrocytes treated with 2 μM Aβ
for the indicated times (0–18 h). (c) Ca2+ influx in astrocytes treated with 2 μM Aβ for 0–60 min. Fluo-8 calcium assay of intracellular level of Ca2+ in (d, e)
primary astrocytes from WT and TRPA1−/− mice treated with Aβ (2 μM) for 2 min and (f, g) astrocytes pretreated with HC030031 (HC) 10 μM, EGTA 0.5 mM
and EDTA 0.5 mM for 2 h, then treated with Aβ for 2 min. Fluorescence images were photographed by fluorescence microscopy. Bar = 100 μm. Data are
mean ± SEM from 5 independent experiments. *, P< 0.05 vs. vehicle or 0 min. #, P< 0.05 vs. WT Aβ treatment or vehicle
Lee et al. Journal of Neuroinflammation  (2016) 13:92 Page 9 of 16
inhibition of TRPA1 channel activity by HC030031 or
genetic manipulation abrogated the Aβ-mediated produc-
tion of IL-1β, IL-6, IL-4 and IL-10 in astrocytes (Fig. 7a-d,
n = 5, P < 0.05). Moreover, pretreatment with HC030031
or genetic disruption of TRPA1 function diminished the
Aβ-induced activation of NF-κB and NFAT (Fig. 7e, f,
n = 5, P < 0.05). Exposure of astrocytes to fibrilized Aβ
elicited astrogliosis, which was aggravated by pharmaco-
logical inhibition or genetic disruption of TRPA1 channel
activity (Fig. 7g). As well, PP2B protein was expressed in
hippocampus astrocytes of both APP/PS1 Tg and APP/PS1
Tg/TRPA1−/− mice (Fig. 8a). Functional ablation of TRPA1
channels in mice on a C57BL or APP/PS1 Tg background
did not affect the protein expression of PP2B (Fig. 8b).
However, genetic deletion of TRPA1 in mice on an APP/
PS1 Tg background decreased PP2B activity in AD brains
(Fig. 8c, n = 8, P < 0.05). Genetic ablation of TRPA1 channel
function, treatment with HC030031, or removal of Ca2+ by
EGTA or EDTA all diminished the Aβ-increased PP2B ac-
tivity in astrocytes (Fig. 8d, e, n = 5, P < 0.05). Moreover,
Fig. 6 The essential role of TRPA1 in Aβ-induced calcium influx in HEK293 cells. (a) Western blot analysis of TRPA1 and α-tubulin protein levels
in non-treated, vector- or TRPA1-transfected HEK293 cells. (b) Ca2+ influx in HEK293 cells transfected with vector or TRPA1 plasmid, then treated
with Aβ (2 μM) for 0–60 min. Fluo-8 calcium assay of the intracellular level of Ca2+ in (c) HEK293 cells transfected with vector or TRPA1 plasmid
for 24 h, then treated with Aβ (2 μM) or AITC (10 μM, a TRPA1 agonist) for 5 min and (d) after transfection with TRPA1 plasmid, HEK293 cells
pretreated with a TRPA1 antagonist HC030031 (HC) 10 μM, EGTA 0.5 mM and EDTA 0.5 mM for 2 h, then with Aβ for 5 min. Fluorescence images
were photographed by fluorescence microscopy. Bar = 100 μm. Data are mean ± SEM from 5 independent experiments. *, P < 0.05 vs. 0 min or
TRPA1 transfection alone. #, P < 0.05 vs. vector-transfection alone or TRPA1 transfection + Aβ treatment
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pharmacological inhibition of PP2B activity by CsA or Fen
prevented the Aβ-induced production of IL-1β, IL-6, IL-4
and IL-10 (Fig. 8f-i, n = 5, P < 0.05) and activation of NF-κB
and NFAT in astrocytes (Fig. 8j, k, n = 5, P < 0.05), as well
as astrogliosis (Fig. 8l). Collectively, these findings strongly
suggest that activation of a TRPA1 −Ca2+ − PP2B signaling
cascade might be an important event in Aβ-induced in-
flammation of astrocytes and AD pathogenesis (Fig. 9).
Discussion
Our study demonstrated the novel role of the TRPA1
channel in astrocytes under an Aβ-elicited inflammatory
environment and thus its potential involvement in AD
pathogenesis. The protein level of the TRPA1 channel was
increased in astrocytes of APP/PS1 Tg mice at 8 months
old as compared with WT mice at the same age. As well,
loss of function of the TRPA1 channel impeded AD pro-
gression, as evidenced by improved nest building ability,
spatial learning and memory and decreased Aβ plaque
deposition and cytokine production in APP/PS1 Tg mice.
In vitro, TRPA1 channels mediated the Aβ-triggered Ca2+
influx and inflammation in astrocytes. Gain of function of
TRPA1 in TRP channel–deficient HEK293 cells further
supports that TRPA1 activation is crucial in Aβ-mediated
Ca2+ influx. Aβ evoked TRPA1-Ca2+ signaling, which in
turn activated PP2B, NF-κB and NFAT. The activation of
these proteins increased the production of inflammatory
cytokines. This inflammatory cascade in our model agreed
with findings by Fernandez et al. and Furman et al., who
established that increased Ca2+ influx is a key event for
activation of PP2B signaling and inflammation in astrocytes
[14–16]. Finally, behavioral analysis demonstrated that
functional loss of TRPA1 ameliorated AD progression and
improved neuropsychiatric signs, positively affecting cogni-
tion and spatial learning and memory. Collectively, our
results suggest that the TRPA1 channel is involved in Aβ-
triggered inflammatory responses of astrocytes and the
development of AD.
The association of deregulated cellular Ca2+ homeostasis
and AD pathogenesis has been established in vitro and
Fig. 7 TRPA1 is crucial in regulating Aβ-induced inflammatory response and astrogliosis in astrocytes. Primary astrocytes from WT and TRPA1−/− mice were
pretreated with HC030031 (HC; 10 μM) for 2 h, then with Aβ (2 μM) for 24 h (a-d) or 1 h (e, f). ELISA of (a-d) IL-1β, IL-6, IL-4 and IL-10 secretion in culture
medium and (e, f) NF-κB and NFAT DNA binding activity in cellular lysates. (g) Immunostaining of astrocytes from treated WT and TRPA1−/− mice with
anti-GFAP antibody, then FITC-conjugated secondary antibody. Bar = 100 μm. Data are mean ± SEM from 5 independent experiments. *, P< 0.05 vs. vehicle.
#, P< 0.05 vs. WT Aβ treatment
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in vivo [41–43]. Emerging evidence further supported the
causal relationship between the impaired Ca2+ homeosta-
sis and synaptic dysfunction and neuronal degeneration of
AD [1]. Specifically, exposure of Aβ to neurons disrupts
Ca2+ homeostasis and causes oxidative damage, thereby
leading to neuronal death and synaptic dysfunction via
multiple receptor-dependent pathways including NMDA
receptor or voltage-gated Ca2+ channels [1]. However,
research into Ca2+ homeostasis of astrocytes and its role
in AD pathogenesis is still in its infancy. Several lines of
evidence indicated that TRP channels such as canonical
(TRPC), melastatin (TRPM), and vanilloid (TRPV) chan-
nels also play a role in AD pathogenesis [44, 45]. Especially,
astrocyte-related inflammation is a key factor in AD pro-
gression [8, 9, 46, 47]. Aβ-induced Ca2+ influx is closely
associated with the inflammatory responses in astrocytes
[11–13]. In astrocytes, Aβ elicits the production of ROS
and nitric oxide (NO), which can activate TRPM2, TRPM7,
TRPC5 and TRPV1 and increase the intracellular level of
Ca2+, thereby leading to AD-related events in the brain in-
cluding neurodegeneration and inflammation [30].
However, how TRPA1 activation, particularly in astro-
cytes, contributes to AD pathogenesis has not been investi-
gated. Our results demonstrated that Aβ triggered TRPA1-
dependent Ca2+ influx and subsequently increased PP2B
activity, which promoted activation of NF-κB and NFAT,
thereby leading to production of pro-inflammatory cyto-
kines from astrocytes. Most importantly, we observed these
key events in our in vivo model. Of note, in astrocytes, both
pretreatment with HC030031 and genetic loss of function
Fig. 8 PP2B activation is vital in Aβ-induced inflammation in astrocytes. (a) Immunostaining of hippocampus specimens from 8-month-old APP/PS1
Tg and APP/PS1 Tg/TRPA1−/− mice with anti-GFAP and anti-PP2B antibodies, then FITC- or Texas red-conjugated secondary antibody. Bar = 50 μm. GFAP-
positive cells (red color) denote astrocytes and FITC-positive cells (green color) denote PP2B protein. (b and c) Western blot analysis of PP2B and its activity
in brain lysates from 8-month-old WT, TRPA1−/−, APP/PS1 Tg and APP/PS1 Tg/TRPA1−/− mice. (d) Primary astrocytes from WT and TRPA1−/− mice were
treated with Aβ (2 μM) for 30 min. (e) WT astrocytes were pretreated with HC (10 μM), 0.5 mM EGTA or 0.5 mM EDTA for 2 h, then Aβ (2 μM) for 30 min.
(f-k) WT astrocytes were pretreated with cyclosporin A (CsA, 100 nM) or fenvalerate (Fen, 100 nM) for 2 h, then with Aβ (2 μM) for 24 h (f-i) or 1 h (j and k).
ELISA of (f-i) IL-1β, IL-6, IL-4 and IL-10 in culture medium and (j, k) NF-κB and NFAT DNA binding activity in cell lysates. (l) Immunostaining of astrocytes
from treated WT mice with anti-GFAP antibody, then FITC-conjugated secondary antibody. Bar = 100 μm. Data are mean ± SEM from 5 independent in vitro
experiments or from 8 mice in each group. *, P< 0.05 vs. vehicle or WT mice. #, P< 0.05 vs. Aβ treatment or APP/PS1 Tg mice
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of TRPA1 channels could only partially obstruct the Aβ-
elicited Ca2+ influx. In contrast, pretreatment with EGTA
and EDTA completely abolished Ca2+ influx induced by
Aβ. These results imply the existence of other routes of Ca2
+ influx triggered by Aβ. Indeed, several proteins regulating
Ca2+ flow on Aβ challenge in astrocytes have been identi-
fied [42, 43]. In response to ligands, TRP channels can form
homo- or heterotetramers or activate other TRP channels,
thereby increasing intracellular Ca2+ level and activating
downstream Ca2+-mediated signaling cascades [48, 49].
However, whether other TRP channels participate in the
Aβ-induced TRPA1 channel activation and if so, how they
activate the TRPA1 channel remains unknown.
PP2B activity of astrocytes is highly associated with
neurodegenerative diseases [50, 51]. Increased numbers of
PP2B-positive astrocytes were found in the immediate
vicinity of extracellular Aβ deposition in patients with
dementia and in an AD mouse model [50, 51]. In addition,
disruption of Ca2+ homeostasis causes hyperactivity of
PP2B signaling cascades, which can amplify the offset
effect of Ca2+ dysregulation [15]. This notion was further
supported by our findings that TRPA1-derived Ca2+
mobilization was critical in Aβ-activated PP2B, as evi-
denced by reduced PP2B activity in TRPA1 antagonist–
treated or TRPA1-deficient astrocytes or brain tissues of
APP/PS1 Tg/TRPA1−/− mice. PP2B can lessen Akt activity
its downstream signaling pathways, which are involved in
inflammation and AD [52–54]. In fact, deletion of TRPA1
decreased PP2B activity but increased the phosphorylation
of Akt in brain tissues of APP/PS1 Tg mice (Additional file
1: Figure S5). Thus, TRPA1 −Ca2+ − PP2B signaling may
play an important role in AD progression. However, the
detailed molecular mechanism by which PP2B regulates
AD progression needs further investigation.
In the AD brain, Aβ plaques surrounding astrocytes can
secrete inflammatory mediators to regulate neuroinflamma-
tion [55]. IL-1β, IL-4, and IL-6 are involved in the initiation
and progression of AD by deregulating Aβ-mediated in-
flammation and APP metabolism [55–57]. In contrast, IL-
10 can limit inflammation by reducing pro-inflammatory
cytokines during AD pathogenesis [55]. In line with these
findings, our data demonstrated lower levels of IL-1β, IL-4,
IL-6, but IL-10 in APP/PS1 Tg/TRPA1−/− mice than APP/
PS1 Tg mice. Moreover, functional inhibition of TRPA1
abrogated the Aβ-triggered production of IL-1β, IL-4 and
IL-6 in astrocytes. The transcriptional factors NF-κB and
NFAT are key regulators in gene expression of IL-1β, IL-4
and IL-6 [37–40]. Consistently, we found that functional
deletion of TRPA1 decreased Aβ-induced NF-κB and
NFAT activity in astrocytes and mice. Nevertheless,
the mechanism underlying TRPA1-mediated regula-
tion of inflammation and AD pathogenesis needs fur-
ther investigation.
Astrogliosis (referred to as reactive astrocytes) occurs
prominently in response to central nervous system injury
or remodeling [9, 58]. Although the biological function of
astrogliosis is not fully understood, reactive astrocytes are
intimately associated with Aβ plaque and involved in the
regulation of neural protection and repair, glial scarring
and neuro-inflammation in the pathogenesis of AD [58].
In addition, reactive astrocytes promote the clearance
and degradation of Aβ in AD brain and thus limit the
growth of Aβ plaque [59]. Interestingly, we found greater
astrogliosis after treatment with a TRPA1 antagonist or
Fig. 9 TRPA1− Ca2+− PP2B signaling pathway in Aβ− triggered activation of NF-κB and NFAT and inflammation in astrocytes. A proposed mechanism by
which TRPA1 channel regulates Aβ-mediated inflammatory response in astrocytes. Aβ fibril activates PP2B, NF-κB and NFAT and, ultimately, production of
pro-inflammatory cytokines in astrocytes
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functional deletion of TRPA1 in vitro and in vivo. In paral-
lel, the neuro-inflammation was ameliorated with both
pharmacological inhibition and genetic deletion of TRPA1
in Aβ-treated astrocytes and mouse brains. Activation of
TRPA1-Ca2+ signaling might be critical in regulating Aβ-
mediated astrogliosis and neuro-inflammation.
APP can be rapidly metabolized by post-translational
proteolysis via an amyloidogenic or non-amyloidogenic
pathway in neurons, and its role in AD is well established
[3, 60]. In the amyloidogenic pathway, APP is cleaved by β-
secretase, and N-terminal APP fragments and βCTF are
produced and released. βCTF is then cleaved by γ-secretase
and generates an amyloid precursor protein intracellular
domain and toxic Aβ peptide (37–49 amino acids), which
triggers inflammation and neuron dysfunction [3, 5, 60]. In
contrast, in the non-amyloidogenic pathway, APP is cleaved
by α-secretase and yields a soluble N-terminal APPα frag-
ment and α-C-terminal fragment (αCTF). αCTF is then
cleaved by γ-secretase to generate non-toxic p83 peptide
(23–25 amino acids) [60, 61]. Disruption of Ca2+ homeosta-
sis may deregulate APP processing and increase Aβ gener-
ation [61]. This notion was supported by our findings that
ablation of TRPA1-Ca2+ signaling decreased Aβ production
and accumulation in the AD mouse brain. Notably, our
results further demonstrated that functional loss of TRPA1
channels increased the levels of βCTF but decreased that of
Aβ in the AD mouse brain. Thus, TRPA1-Ca2+ signaling
might regulate APP processing, especially at the step of
cleavage of βCTF to Aβ generation.
Previous evidence linked cholesterol metabolism of the
brain to Aβ clearance [62, 63]. Astrocyte-derived apoE-
containing high-density lipoprotein-like particles play a
central role in neural repair during AD development
[62–64]. These particles can be transported by ABCA1
into the extracellular space to bind with Aβ and then are
taken up by neurons, astrocytes and microglia through
LRP-1 to remove the Aβ deposition [63]. The expression
of ABCA1 and LRP-1 is increased with AD progression
[65, 66]. We found that functional loss of TRPA1 chan-
nels decreased the expression of ABCA1 and LRP-1
without altering apoE expression and its co-localization
with Aβ plaque in APP/PS1 Tg mice. As we described
previously, Aβ accumulation was lower in the brain of
APP/PS1 Tg/TRPA1−/− than APP/PS1 Tg mice, so APP/
PS1 Tg/TRPA1−/− mice might not need such levels of
ABCA1 and LRP-1 to clear Aβ. Nevertheless, we cannot
conclude that TRPA1 channels are a negative regulator
of Aβ clearance based on these observations.
Conclusions
In conclusion, we provide experimental evidence to sup-
port the critical role of TRPA1-Ca2+ signaling in regulating
Aβ-triggered inflammation and AD progression. The mo-
lecular mechanisms we established may provide important
information for depicting the pathogenesis of AD and aid
in the development of therapeutic interventions for AD
and other neurodegenerative diseases.
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